Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:630124.
doi: 10.1155/2012/630124. Epub 2012 Oct 21.

Clinical efficacy and safety of buyang huanwu decoction for acute ischemic stroke: a systematic review and meta-analysis of 19 randomized controlled trials

Chi-Zi Hao  1 , Fan Wu, Jiangang Shen, Lin Lu, Deng-Lei Fu, Wei-Jing Liao, Guo-Qing Zheng
Affiliations

Clinical efficacy and safety of buyang huanwu decoction for acute ischemic stroke: a systematic review and meta-analysis of 19 randomized controlled trials

Chi-Zi Hao et al. Evid Based Complement Alternat Med. 2012.

Abstract

Buyang Huanwu Decoction (BHD) is a well-known traditional Chinese herbal prescription for treating stroke-induced disability. The objective of this study was to evaluate the efficacy and safety of BHD for acute ischemic stroke. A systematic literature search was performed in 6 databases until February 2012. Randomized controlled clinical trials (RCTs) that evaluate efficacy and safety of BHD for acute ischemic stroke were included. Nineteen RCTs with 1580 individuals were identified. The studies were generally of low methodological quality. Only one of the trial included death or dependency as a primary outcome measure. Only 4 trials reported adverse events. Meta-analysis showed the clinical effective rate of neurological deficit improvement favoring BHD when compared with western conventional medicines (WCM), P < 0.001. There is significant difference in the neurologic deficit score between the BHD treatment group and the WCM control group, P < 0.001. In Conclusion, BHD appears to improve neurological deficit and seems generally safe in patients with acute ischemic stroke. However, the current evidence is insufficient to support a routine use of BHD for acute ischemic stroke due to the poor methodological quality and lack of adequate safety data of the included studies. Further rigorously designed trials are required.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of trials selection process.
Figure 2
Figure 2
Funnel plot of the total effective rate of BHD therapy for acute ischemic stroke.
Figure 3
Figure 3
Funnel plot of the scores of neurological deficit of BHD therapy for acute ischemic stroke.
See this image and copyright information in PMC

References

    1. Feigin VL, Lawes CMM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. The Lancet Neurology. 2003;2(1):43–53. - PubMed
    1. World Health Organization. STEPwise approach to stroke surveillance. http://www.who.int/chp/steps/stroke/en/index.html.
    1. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. The Lancet Neurology. 2009;8(4):345–354. - PubMed
    1. Panagos PD. The approach to optimizing stroke care. The American Journal of Emergency Medicine. 2008;26(7):808–816. - PubMed
    1. Liu Z, Guan L, Wang Y, Xie CL, Lin XM, Zheng GQ. History and mechanism for treatment of intracerebral hemorrhage with scalp acupuncture. Evidence-Based Complementary and Alternative Medicine. 2012;2012:9 pages.895032 - PMC - PubMed

LinkOut - more resources